Tarsus Pharmaceuticals (TARS) Receivables (2020 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Receivables of $117.2 million for Q1 2026, up 82.7% year-over-year from $64.2 million in Q1 2025, and up 37.26% quarter-over-quarter from $85.4 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Receivables (2020 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Receivables history runs 7 years deep, the most recent figure standing at $117.2 million for Q1 2026.
- In Q1 2026, Receivables rose 82.7% year-over-year to $117.2 million; the TTM figure through Mar 2026 stood at $117.2 million (up 82.7% YoY), while the FY2025 annual figure was $87.1 million, up 81.25% from the prior year.
- Receivables for Q1 2026 stood at $117.2 million, up from $85.4 million in the prior quarter.
- The five-year high for Receivables was $117.2 million in Q1 2026, with the low at -$665000.0 in Q1 2023.
- The 5-year median for Receivables is $30.6 million (2024), against an average of $35.7 million.
- The sharpest annual moves came in 2022 and 2023: Receivables surged 7886.96% in 2022, then sank 305.88% in 2023.
- Tarsus Pharmaceuticals' Receivables stood at $3.6 million in 2022, then surged by 366.36% to $16.7 million in 2023, then surged by 180.84% to $46.9 million in 2024, then surged by 82.02% to $85.4 million in 2025, then soared by 37.26% to $117.2 million in 2026.
- Business Quant data shows TARS's Receivables at $117.2 million in Q1 2026, $85.4 million in Q4 2025, and $74.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 98.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.31 Mn |
| Mar 31, 2026 | 117.21 Mn |
| Dec 31, 2025 | 85.39 Mn |
| Sep 30, 2025 | 74.34 Mn |
| Jun 30, 2025 | 60.24 Mn |
| Mar 31, 2025 | 64.15 Mn |
| Dec 31, 2024 | 46.91 Mn |
| Sep 30, 2024 | 30.30 Mn |
| Jun 30, 2024 | 30.84 Mn |
| Mar 31, 2024 | 31.36 Mn |
| Dec 31, 2023 | 16.71 Mn |
| Sep 30, 2023 | 6.37 Mn |
| Mar 31, 2023 | -665,000.00 |
| Dec 31, 2022 | 3.58 Mn |
| Sep 30, 2022 | 3.41 Mn |
| Jun 30, 2022 | 620,000.00 |
| Mar 31, 2022 | 323,000.00 |
| Dec 31, 2021 | -46,000.00 |
| Jun 30, 2021 | 20.16 Mn |
| Mar 31, 2021 | 25.25 Mn |